摘要
2型糖尿病是心房颤动发生的独立危险因素,进展到糖尿病肾病(DN)时发生心房颤动的风险倍增,并发心房颤动预后变差。非奈利酮是一种非甾体盐皮质激素受体拮抗剂,对心力衰竭、慢性肾脏病患者的心脏和肾脏具有保护作用。研究表明,非奈利酮在治疗糖尿病相关慢性肾脏病的同时降低了心房颤动的发生率,给DN患者防治心房颤动带来了新希望。
Type 2 diabetes mellitus is an independent risk factor for the occurrence of atrial fibrillation.The risk of atrial fibrillation is multiplied in diabetic nephropathy(DN),and the prognosis complicated with atrial fibrillation becomes worse.Finerenone,a nonsteroidal corticosteroid receptor antagonist,which has a protective effect on the heart and kidney in patients with heart failure and chronic kidney disease.Finerenone has been shown to reduce the incidence of atrial fibrillation in the treatment of diabetes-related chronic kidney disease,providing new hope for the prevention and treatment to the occurence of atrial fibrillation for patients with diabetic nephropathy.
作者
刘离香
刘永铭
LIU Li-xiang;LIU Yong-ming(The First Clinical Medical College of Lanzhou University,Lanzhou 730000,China;Geriatric Cardiovascular Department,The First Hospital of Lanzhou University,Gansu Provincial Clinical Research Center for Geriatric Diseases,Lanzhou 730000,China)
出处
《中国心血管病研究》
CAS
2023年第6期505-510,共6页
Chinese Journal of Cardiovascular Research
关键词
非奈利酮
糖尿病肾病
慢性肾脏病
心房颤动
Finerenone
Diabeticnephropathy
Chronic kidney disease
Atrial fibrillation
